On June 25, Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology firm and inventors of V-Go® Wearable Insulin Delivery device disclosed positive results from the EffectiveNess of V-Go WeArable Insulin Delivery for Basal-BoLus ThErapy (ENABLE) Study. V-Go Wearable Insulin Delivery device is a simple, all-in-one, wearable insulin delivery option for patients with diabetes
Presentations from three posters at the American Diabetes Association Meeting in Orlando, Florida, reported that patients who shifted from insulin pens and syringes to V-Go eloquently improved blood glucose while decreasing insulin dose.
John Timberlake, Valeritas Chief Executive Officer stated that the biggest study of V-Go patients to date has shown that, regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go eloquently decreased their blood glucose. He believes is significant for diabetes patients, payer’s, Valeritas and their medical professionals.
Mr. Timberlake went on to state that they recently announced their third consecutive quarter of record revenue which is a direct result of V-Go gaining momentum among patients with type 2 diabetes. V-Go is discreet, easy-to-use, cost-effective, clinically proven and the only disposable, daily insulin delivery alternative.
ENABLE study of world wvaluation in Type 2 Diabetes.
The first ENABLE Study poster judged the clinical advantages in patients with type 2 diabetes who shifted from using insulin pens and syringes to dispense their insulin regimen with V-Go for insulin delivery. The 283 patient, retrospective study manifested clinically and statistically significant decrease in A1C by over 1% and insulin total daily dose (TDD) at three and seven months. The percent of patients at high risk (A1C > 9%) was decreased by almost 50% after shifting to V-Go. Moreover, over 50% of all patients in the study achieved an A1C less than 8%.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Patients with an A1C over 9.0% are categorized as high risk because they are more likely to have long-term difficulties that affect health care costs. The significant decrease in A1C and the achievement in A1C goals after shifting to V-Go in the ENABLE study has significant implications for treating diabetes. By improving glycemic control, our hope is to decrease rates of complications as well as reduce health care cost, which is a priority for all healthcare systems.
The second review from the ENABLE study verified V-Go delivered a clinical advantage in a patient population poorly controlled on conventional basal-bolus therapy offered by multiple daily injections (MDI) using insulin pens and syringes.
Clinical results with V-Go in Type 2 Diabetes
ENABLE third study poster evaluated the effect of duration of diabetes on change in A1C and insulin TDD when shifting patients with type 2 diabetes from insulin delivery through insulin pen or syringe to V-Go.
Data from the ENABLE Study showed that no matter how long a patient had been diagnosed with diabetes, shifting to V-Go from insulin delivery via insulin pens and syringes led to eloquently lower A1C levels. This positive data proves that diabetes duration should not be a factor when determining which patient can gain from using V-Go.